|
|
Article: HGS GETS ADDITIONAL ANTIBODY TECHNOLOGY IN $67M CAT DEAL.(Brief Article)
- Article from:
- BIOWORLD Today
- Article date:
- March 2, 2000
- Author:
CopyrightCOPYRIGHT 2000 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Chasing big profits in genomics has become a CAT-and- mouse game for Human Genome Sciences Inc. (HGS), and William Haseltine, chairman and CEO, said he believes his company's latest deal has the market cornered.
Just three months after signing an agreement with Abgenix Inc. for human antibodies using that company's transgenic mouse, Rockville, Md.-based HGS reached across the ocean to enter a $67 million collaboration with England-based Cambridge Antibody Technology plc (CAT), for access to its phage display technology.
Under the terms of the agreement, HGS may use CAT's technology to pursue not only its own drugs, but to forge collaborations with other ...